•
Dec 31, 2021
Rigel Q4 2021 Earnings Report
Reported a net loss, revenues from TAVALISSE sales and contract revenues, and increased costs and expenses due to research and development costs and commercial activities.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $22.6 million for the fourth quarter of 2021, with total revenues of $20.4 million, including $17.6 million from TAVALISSE net product sales and $2.8 million from contract revenues. The company's costs and expenses increased to $41.8 million due to research and development and commercial activities.
Net loss for Q4 2021 was $22.6 million, or $0.13 per basic and diluted share.
Total revenues for Q4 2021 were $20.4 million.
TAVALISSE net product sales for Q4 2021 were $17.6 million, a 1% decrease from Q4 2020.
Total costs and expenses for Q4 2021 were $41.8 million.
Rigel
Rigel
Forward Guidance
Rigel anticipates reporting Phase 3 fostamatinib results from both wAIHA and COVID-19 trials in mid-2022.